BAGSVÆRD, DENMARK--(Marketwire - January 30, 2009) - Trading in Novo Nordisk shares by board members, executives and associated persons as reported to Novo Nordisk on 29 January 2009
In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons as reported by those persons to Novo Nordisk.
As from 2004, members of Novo Nordisk’s Executive Management and other members of the Senior Management Board have participated in a performance based incentive programme where a proportion of the calculated shareholder value creation has been allocated to a joint pool for the participants. For 2005, 232,026 shares were allocated to the joint pool and the market value of the scheme was expensed in the account s for 2005. In accordance with the principles of the incentive program, the Board of Directors of Novo Nordisk A/S on 28 January 2009 evaluated that the conditions for release of the joint pool of shares have been fulfilled. Accordingly, the shares in the joint pool were transferred to 23 current and former members of senior management on 29 January 2009.
Further, members of Executive Management have traded shares through the exercise of options.
Please find below a statement of such trading in shares issued by Novo Nordisk.
+-------------------------------------------------------------------+ | Name | Lars Rebien Sørensen | |--------------------------+----------------------------------------| | Reason for reporting | Chief Executive Officer | |--------------------------+----------------------------------------| | Financial instrument and | Novo Nordisk B DK006010261 | | ID code | | |--------------------------+----------------------------------------| | Type of transaction | Other transaction (transfer of shares | | | in accordance with long-term incentive | | | programme) | |--------------------------+----------------------------------------| | Date of transaction | 29 January 2009 | |--------------------------+----------------------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |--------------------------+----------------------------------------| | Volume of transaction | 23,208 shares | |--------------------------+----------------------------------------| | Total value of | 0 (transferred in accordance with the | | transaction | long-term incentive programme for | | | 2005) | +-------------------------------------------------------------------+
+---------------------------------------------------------------+ | Name | Lars Rebien Sørensen | |----------------------------------+----------------------------| | Reason for reporting | Chief Executive Officer | |----------------------------------+----------------------------| | Financial instrument and ID code | Novo Nordisk B DK006010261 | |----------------------------------+----------------------------| | Type of transaction | Sale of shares | |----------------------------------+----------------------------| | Date of transaction | 29 January 2009 | |----------------------------------+----------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |----------------------------------+----------------------------| | Volume of transaction | 23,208 shares | |----------------------------------+----------------------------| | Total value of transaction | DKK 6,926,196 | +---------------------------------------------------------------+
+-------------------------------------------------------------------+ | Name | Lars Rebien Sørensen | |-----------------------------+-------------------------------------| | Reason for reporting | Chief Executive Officer | |-----------------------------+-------------------------------------| | Financial instrument and ID | Novo Nordisk B DK006010261 | | code | | |-----------------------------+-------------------------------------| | Type of transaction | Exercise of options (purchase of | | | shares) | |-----------------------------+-------------------------------------| | Date of transaction | 29 January 2009 | |-----------------------------+-------------------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |-----------------------------+-------------------------------------| | Volume of transaction | 22,000 shares | |-----------------------------+-------------------------------------| | Total value of transaction | DKK 2,178,000 | +-------------------------------------------------------------------+
+---------------------------------------------------------------+ | Name | Lars Rebien Sørensen | |----------------------------------+----------------------------| | Reason for reporting | Chief Executive Officer | |----------------------------------+----------------------------| | Financial instrument and ID code | Novo Nordisk B DK006010261 | |----------------------------------+----------------------------| | Type of transaction | Sale of shares | |----------------------------------+----------------------------| | Date of transaction | 29 January 2009 | |----------------------------------+----------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |----------------------------------+----------------------------| | Volume of transaction | 12,000 shares | |----------------------------------+----------------------------| | Total value of transaction | DKK 3,581,280 | +---------------------------------------------------------------+
+-------------------------------------------------------------------+ | Name | Jesper Brandgaard | |--------------------------+----------------------------------------| | Reason for reporting | Chief Financial Officer | |--------------------------+----------------------------------------| | Financial instrument and | Novo Nordisk B DK006010261 | | ID code | | |--------------------------+----------------------------------------| | Type of transaction | Other transaction (transfer of shares | | | in accordance with long-term incentive | | | programme) | |--------------------------+----------------------------------------| | Date of transaction | 29 January 2009 | |--------------------------+----------------------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |--------------------------+----------------------------------------| | Volume of transaction | 15,468 shares | |--------------------------+----------------------------------------| | Total value of | 0 (transferred in accordance with the | | transaction | long-term incentive programme for | | | 2005) | +-------------------------------------------------------------------+
+---------------------------------------------------------------+ | Name | Jesper Brandgaard | |----------------------------------+----------------------------| | Reason for reporting | Chief Financial Officer | |----------------------------------+----------------------------| | Financial instrument and ID code | Novo Nordisk B DK006010261 | |----------------------------------+----------------------------| | Type of transaction | Sale of shares | |----------------------------------+----------------------------| | Date of transaction | 29 January 2009 | |----------------------------------+----------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |----------------------------------+----------------------------| | Volume of transaction | 15,468 shares | |----------------------------------+----------------------------| | Total value of transaction | DKK 4,616,270 | +---------------------------------------------------------------+
+-------------------------------------------------------------------+ | Name | Jesper Brandgaard | |-----------------------------+-------------------------------------| | Reason for reporting | Chief Financial Officer | |-----------------------------+-------------------------------------| | Financial instrument and ID | Novo Nordisk B DK006010261 | | code | | |-----------------------------+-------------------------------------| | Type of transaction | Exercise of options (purchase of | | | shares) | |-----------------------------+-------------------------------------| | Date of transaction | 29 January 2009 | |-----------------------------+-------------------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |-----------------------------+-------------------------------------| | Volume of transaction | 12,000 shares | |-----------------------------+-------------------------------------| | Total value of transaction | DKK 1,188,000 | +-------------------------------------------------------------------+
+---------------------------------------------------------------+ | Name | Jesper Brandgaard | |----------------------------------+----------------------------| | Reason for reporting | Chief Financial Officer | |----------------------------------+----------------------------| | Financial instrument and ID code | Novo Nordisk B DK006010261 | |----------------------------------+----------------------------| | Type of transaction | Sale of shares | |----------------------------------+----------------------------| | Date of transaction | 29 January 2009 | |----------------------------------+----------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |----------------------------------+----------------------------| | Volume of transaction | 12,000 shares | |----------------------------------+----------------------------| | Total value of transaction | DKK 3,581,280 | +---------------------------------------------------------------+
+-------------------------------------------------------------------+ | Name | Lise Kingo | |--------------------------+----------------------------------------| | Reason for reporting | Chief of Staffs | |--------------------------+----------------------------------------| | Financial instrument and | Novo Nordisk B DK006010261 | | ID code | | |--------------------------+----------------------------------------| | Type of transaction | Other transaction (transfer of shares | | | in accordance with long-term incentive | | | programme) | |--------------------------+----------------------------------------| | Date of transaction | 29 January 2009 | |--------------------------+----------------------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |--------------------------+----------------------------------------| | Volume of transaction | 15,468 shares | |--------------------------+----------------------------------------| | Total value of | 0 (transferred in accordance with the | | transaction | long-term incentive programme for | | | 2005) | +-------------------------------------------------------------------+
+---------------------------------------------------------------+ | Name | Lise Kingo | |----------------------------------+----------------------------| | Reason for reporting | Chief of Staffs | |----------------------------------+----------------------------| | Financial instrument and ID code | Novo Nordisk B DK006010261 | |----------------------------------+----------------------------| | Type of transaction | Sale of shares | |----------------------------------+----------------------------| | Date of transaction | 29 January 2009 | |----------------------------------+----------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |----------------------------------+----------------------------| | Volume of transaction | 15,468 shares | |----------------------------------+----------------------------| | Total value of transaction | DKK 4,616,270 | +---------------------------------------------------------------+
+-------------------------------------------------------------------+ | Name | Kåre Schultz | |--------------------------+----------------------------------------| | Reason for reporting | Chief Operating Officer | |--------------------------+----------------------------------------| | Financial instrument and | Novo Nordisk B DK006010261 | | ID code | | |--------------------------+----------------------------------------| | Type of transaction | Other transaction (transfer of shares | | | in accordance with long-term incentive | | | programme) | |--------------------------+----------------------------------------| | Date of transaction | 29 January 2009 | |--------------------------+----------------------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |--------------------------+----------------------------------------| | Volume of transaction | 15,468 shares | |--------------------------+----------------------------------------| | Total value of | 0 (transferred in accordance with the | | transaction | long-term incentive programme for | | | 2005) | +-------------------------------------------------------------------+
+---------------------------------------------------------------+ | Name | Kåre Schultz | |----------------------------------+----------------------------| | Reason for reporting | Chief Operating Officer | |----------------------------------+----------------------------| | Financial instrument and ID code | Novo Nordisk B DK006010261 | |----------------------------------+----------------------------| | Type of transaction | Sale of shares | |----------------------------------+----------------------------| | Date of transaction | 29 January 2009 | |----------------------------------+----------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |----------------------------------+----------------------------| | Volume of transaction | 8,214 shares | |----------------------------------+----------------------------| | Total value of transaction | DKK 2,451,386 | +---------------------------------------------------------------+
+-------------------------------------------------------------------+ | Name | Mads Krogsgaard Thomsen | |--------------------------+----------------------------------------| | Reason for reporting | Chief Science Officer | |--------------------------+----------------------------------------| | Financial instrument and | Novo Nordisk B DK006010261 | | ID code | | |--------------------------+----------------------------------------| | Type of transaction | Other transaction (transfer of shares | | | in accordance with long-term incentive | | | programme) | |--------------------------+----------------------------------------| | Date of transaction | 29 January 2009 | |--------------------------+----------------------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |--------------------------+----------------------------------------| | Volume of transaction | 15,468 shares | |--------------------------+----------------------------------------| | Total value of | 0 (transferred in accordance with the | | transaction | long-term incentive programme for | | | 2005) | +-------------------------------------------------------------------+
+---------------------------------------------------------------+ | Name | Mads Krogsgaard Thomsen | |----------------------------------+----------------------------| | Reason for reporting | Chief Science Officer | |----------------------------------+----------------------------| | Financial instrument and ID code | Novo Nordisk B DK006010261 | |----------------------------------+----------------------------| | Type of transaction | Sale of shares | |----------------------------------+----------------------------| | Date of transaction | 29 January 2009 | |----------------------------------+----------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |----------------------------------+----------------------------| | Volume of transaction | 4,000 shares | |----------------------------------+----------------------------| | Total value of transaction | DKK 1,193,760 | +---------------------------------------------------------------+
+-------------------------------------------------------------------+ | Name | Mads Krogsgaard Thomsen | |-----------------------------+-------------------------------------| | Reason for reporting | Chief Science Officer | |-----------------------------+-------------------------------------| | Financial instrument and ID | Novo Nordisk B DK006010261 | | code | | |-----------------------------+-------------------------------------| | Type of transaction | Exercise of options (purchase of | | | shares) | |-----------------------------+-------------------------------------| | Date of transaction | 29 January 2009 | |-----------------------------+-------------------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |-----------------------------+-------------------------------------| | Volume of transaction | 12,000 shares | |-----------------------------+-------------------------------------| | Total value of transaction | DKK 1,188,000 | +-------------------------------------------------------------------+
+---------------------------------------------------------------+ | Name | Mads Krogsgaard Thomasen | |----------------------------------+----------------------------| | Reason for reporting | Chief Science Officer | |----------------------------------+----------------------------| | Financial instrument and ID code | Novo Nordisk B DK006010261 | |----------------------------------+----------------------------| | Type of transaction | Sale of shares | |----------------------------------+----------------------------| | Date of transaction | 29 January 2009 | |----------------------------------+----------------------------| | Place of transaction | NASDAQ OMX Copenhagen | |----------------------------------+----------------------------| | Volume of transaction | 12,000 shares | |----------------------------------+----------------------------| | Total value of transaction | DKK 3,581,280 | +---------------------------------------------------------------+
Definitions and background information:
Publication Publication shall take place the day after Novo Nordisk receives sufficient information on the trading. Publication is only required when the total amount of transactions of a specific board member/executive and his/her associated persons in any one calendar year has reached 5,000 euros.
Who are board members, executives and associated persons? Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) relatives defined as brothers, sisters, parents, grandparents etc, children, grandchildren etc who have shared the same household with a board member/executive for at least one year, and 4) any legal person, including a company, a foundation or a partnership, which is controlled directly or indirectly by a board member/executive and/or a person mentioned in 1)-3), or to which a board member/executive and/or a person mentioned in 1)-3) has managerial responsibilities or economic interests substantially equivalent to the legal person.
What is trading/transaction? Trading is any kind of transaction, including shares purchased or otherwise acquired, shares sold or otherwise disposed, gifts, mortgages and grants and exercise of options, but not heritage.
What is financial instrument and ID code? Financial instrument includes shares listed on the NASDAQ OMX Copenhagen and London Stock Exchange as well as ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees. The ID code is the code (ISIN DK006010261) of the Novo Nordisk share on the NASDAQ OMX Copenhagen, the code (NVOB) on London Stock Exchange or the code (NVO) on New York Stock Exchange.
What is date and place of transaction? Date of transaction is the actual transaction date. The place of transaction is the actual place of transaction, ie NASDAQ OMX Copenhagen, London Stock Exchange or New York Stock Exchange.
What is volume and value of transaction? The volume of transaction is the number of shares (of DKK 1 nominal value) or other financial instruments traded. The transaction value is the number of shares traded multiplied by the transaction price. The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of shares traded on London Stock Exchange and ADRs listed on New York Stock Exchange.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs over 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America: Mike Rulis Mads Veggerby Lausten Tel: (+45) 4442 3573 Tel: (+45) 4443 7919: E-mail: mike@novonordisk.com E-mail:mlau@novonordisk.com Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 E-mail: krop@novonordisk.com
In North America: In North America Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 E-mail: secl@novonordisk.com E-mail: hrmm@novonordisk.com
Company Announcement no 3 / 2009
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
